Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-18T16:17:08.314Z Has data issue: false hasContentIssue false

Nootropics: Emergents drugs associated with new clinical challenges

Published online by Cambridge University Press:  23 March 2020

H. Saiz Garcia
Affiliation:
Complejo Hospitalario Navarra, Psychiatry, Pamplona, Spain
L. Montes Reula
Affiliation:
Complejo Hospitalario Navarra, Psychiatry, Pamplona, Spain
A. Portilla Fernandez
Affiliation:
Complejo Hospitalario Navarra, Psychiatry, Pamplona, Spain
V. Pereira Sanchez
Affiliation:
Clinica Universidad de Navarra, Psychiatry, Pamplona, Spain
N. Olmo Lopez
Affiliation:
CSM Salburua, Psychiatry, Vitoria, Spain
E. Mancha Heredero
Affiliation:
Complejo Hospitalario Navarra, Psychiatry, Pamplona, Spain
A.S. Rosero Enriquez
Affiliation:
Complejo Hospitalario Navarra, Psychiatry, Pamplona, Spain
M.E. Martinez Parreño
Affiliation:
Complejo Hospitalario Navarra, Psychiatry, Pamplona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The “nootropic” or simplified as a “smart drug”, is a common term that will tag along with the compound responsible for the enhancement of mental performance. Certain individuals with a history of mental or substance use disorders might be particularly vulnerable to its adverse effects.

Methodology

A review was conducted aiming to clarify the mechanisms associated of how these drugs increase mental functions including memory, motivation, concentration, and attention; and which kind of individuals are at risk of developing adverse effects when taking these drugs. The literature search was conducted in PubMed data reviewing articles dating between 2015 and 2016.

Results

– Glutaminergic Signalling, Cholinergic System, Amyloid Precursor Protein and Secondary Messenger may be related to the cognitive enhancement achieved by Nootropics. Others, like insulin and angiotensin receptor may involved too.

– Some of them, like Ginkgo biloba, seem to have neuroprotective effects observed in human and animal models, acting as antioxidant and antiapoptotic, also inducing inhibition effects against caspase-3 activation and amyloid-aggregation toward Alzheimer's disease.

– Synthetic nootropics, a lab created compound such as piracetam, especially in people with history of drug abuse, may be associated with psychiatric exacerbations of some patients.

Conclusions

Young adults all over Europe, especially university students, are starting to use nootropic drugs to improve their academic results. Some of them seem to have beneficial effects over mental health but others are sometimes related with sudden and unexplained exacerbations in stable psychiatric patients. It is important to early identify symptoms and to treat them properly.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster viewing: Substance related and addictive disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.